Treatment-emergent AEs grade 3 or 4 occurring in ≥5% of patients across the pomalidomide dosing cohorts
| . | Grade 3 and 4 . | All Grades . | ||||
|---|---|---|---|---|---|---|
| AEs, n (%) . | POM 2 mg (n = 6) . | POM 3 mg (n = 8) . | POM 4 mg (n = 14) . | POM 5 mg (n = 10) . | POM Total (N = 38) . | POM Total (N = 38) . |
| Neutropenia | 1 (17) | 4 (50) | 7 (50) | 8 (80) | 20 (53) | 23 (61) |
| Anemia | 4 (67) | 2 (25) | 2 (14) | 0 | 8 (21) | 17 (45) |
| Thrombocytopenia | 2 (33) | 2 (25) | 1 (7) | 2 (20) | 7 (18) | 10 (26) |
| Sepsis | 1 (17) | 2 (25) | 0 | 1 (10) | 4 (11) | 4 (11) |
| Pneumonia | 1 (17) | 0 | 2 (14) | 0 | 3 (8) | 5 (13) |
| Fatigue | 2 (33) | 1 (13) | 2 (14) | 1 (10) | 6 (16) | 27 (66) |
| Back pain | 1 (17) | 0 | 0 | 1 (10) | 2 (5) | 8 (21) |
| Muscle weakness | 0 | 0 | 2 (14) | 0 | 2 (5) | 2 (5) |
| Renal failure | 1 (17) | 0 | 1 (7) | 0 | 2 (5) | 2 (5) |
| DVT | 0 | 0 | 1 (7) | 1 (10) | 2 (5) | 2 (5) |
| . | Grade 3 and 4 . | All Grades . | ||||
|---|---|---|---|---|---|---|
| AEs, n (%) . | POM 2 mg (n = 6) . | POM 3 mg (n = 8) . | POM 4 mg (n = 14) . | POM 5 mg (n = 10) . | POM Total (N = 38) . | POM Total (N = 38) . |
| Neutropenia | 1 (17) | 4 (50) | 7 (50) | 8 (80) | 20 (53) | 23 (61) |
| Anemia | 4 (67) | 2 (25) | 2 (14) | 0 | 8 (21) | 17 (45) |
| Thrombocytopenia | 2 (33) | 2 (25) | 1 (7) | 2 (20) | 7 (18) | 10 (26) |
| Sepsis | 1 (17) | 2 (25) | 0 | 1 (10) | 4 (11) | 4 (11) |
| Pneumonia | 1 (17) | 0 | 2 (14) | 0 | 3 (8) | 5 (13) |
| Fatigue | 2 (33) | 1 (13) | 2 (14) | 1 (10) | 6 (16) | 27 (66) |
| Back pain | 1 (17) | 0 | 0 | 1 (10) | 2 (5) | 8 (21) |
| Muscle weakness | 0 | 0 | 2 (14) | 0 | 2 (5) | 2 (5) |
| Renal failure | 1 (17) | 0 | 1 (7) | 0 | 2 (5) | 2 (5) |
| DVT | 0 | 0 | 1 (7) | 1 (10) | 2 (5) | 2 (5) |